鞘内注射巴氯芬疗法：益处与并发症
Intrathecal baclofen therapy: benefits and complications.
作者信息
Zdolsek Helena Aniansson, Olesch Christine, Antolovich Giuliana, Reddihough Dinah
机构信息
Department of Developmental Medicine, Royal Children's Hospital, and University of Melbourne, Melbourne, Australia.
出版信息
J Intellect Dev Disabil. 2011 Sep;36(3):207-13. doi: 10.3109/13668250.2011.595707. Epub 2011 Aug 10.
BACKGROUND
Spasticity and dystonia in children with cerebral palsy has been treated with intrathecal baclofen therapy (ITB) at the Royal Children's Hospital, Melbourne, Australia (RCH) since 1999.
METHODS
The records of children having received or still receiving ITB during the period September 1999 until August 2005 were studied to evaluate complications and side effects. Parents answered a questionnaire focused on the health and functional impact in the children.
RESULTS
There were 18 first insertions of pumps, 6 removals, and 4 reinsertions. The longest treatment was 5 years and 11 months and was still ongoing. Seventeen complications occurred in 14 out of 18 children. Despite the high complication rate and the lack of significant functional improvement, 11 out of 12 parents agreed that ITB was beneficial.
CONCLUSION
ITB treatment at RCH over the years has resulted in some complications, mostly occurring shortly after pump insertion. For the majority of children there are substantial benefits.
背景
自1999年以来，澳大利亚墨尔本皇家儿童医院（RCH）一直采用鞘内注射巴氯芬疗法（ITB）治疗脑瘫患儿的痉挛和肌张力障碍。
方法
研究1999年9月至2005年8月期间接受或仍在接受ITB治疗的患儿记录，以评估并发症和副作用。家长回答了一份关于对患儿健康和功能影响的问卷。
结果
共进行了18次首次泵植入、6次移除和4次重新植入。最长治疗时间为5年11个月，仍在进行中。18名儿童中有14名出现了17例并发症。尽管并发症发生率高且功能改善不显著，但12名家长中有11名认为ITB是有益的。
结论
多年来RCH的ITB治疗导致了一些并发症，大多发生在泵植入后不久。对大多数儿童来说，仍有很大益处。
Zotero 插件